Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4
MP Rettig, G Ansstas, JF DiPersio - Leukemia, 2012 - nature.com
Successful hematopoietic stem cell transplant requires the infusion of a sufficient number of
hematopoietic stem/progenitor cells (HSPCs) that are capable of homing to the bone marrow …
hematopoietic stem/progenitor cells (HSPCs) that are capable of homing to the bone marrow …
Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers
E De Clercq - Pharmacology & therapeutics, 2010 - Elsevier
AMD3100 was originally discovered as an anti-HIV agent effective in inhibiting the
replication of HIV in vitro at nanomolar concentrations. We found it to be a potent and …
replication of HIV in vitro at nanomolar concentrations. We found it to be a potent and …
Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-β
SA Patel, JR Meyer, SJ Greco, KE Corcoran… - The Journal of …, 2010 - journals.aai.org
Mesenchymal stem cells (MSCs) have been shown to support breast cancer growth.
Because MSCs also increase the frequency of regulatory T cells (T regs), this study tested …
Because MSCs also increase the frequency of regulatory T cells (T regs), this study tested …
Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU …
RF Duarte, BE Shaw, P Marin, P Kottaridis… - Bone Marrow …, 2011 - nature.com
Plerixafor was recently approved by the US Food and Drug Administration (FDA) and the
European Medicines Evaluation Agency (EMEA) to enhance stem cell mobilization for …
European Medicines Evaluation Agency (EMEA) to enhance stem cell mobilization for …
Ulocuplumab (BMS-936564/MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen …
MK Kashyap, D Kumar, H Jones… - …, 2015 - pmc.ncbi.nlm.nih.gov
The CXCR4 receptor (Chemokine CXC motif receptor 4) is highly expressed in different
hematological malignancies including chronic lymphocytic leukemia (CLL). The CXCR4 …
hematological malignancies including chronic lymphocytic leukemia (CLL). The CXCR4 …
Gold Nanoclusters Doped with 64Cu for CXCR4 Positron Emission Tomography Imaging of Breast Cancer and Metastasis
As an emerging class of nanomaterial, nanoclusters hold great potential for biomedical
applications due to their unique sizes and related properties. Herein, we prepared a 64Cu …
applications due to their unique sizes and related properties. Herein, we prepared a 64Cu …
Chemokine 25–induced signaling suppresses colon cancer invasion and metastasis
Chemotactic cytokines (chemokines) can help regulate tumor cell invasion and metastasis.
Here, we show that chemokine 25 (CCL25) and its cognate receptor chemokine receptor 9 …
Here, we show that chemokine 25 (CCL25) and its cognate receptor chemokine receptor 9 …
Dual CXCR4 and E-selectin inhibitor, GMI-1359, shows anti-bone metastatic effects and synergizes with docetaxel in prostate cancer cell intraosseous growth
Metastatic castration resistant prostate cancer (mCRPC) relapses due to acquired resistance
to docetaxel-based chemotherapy and remains a major threat to patient survival. In this …
to docetaxel-based chemotherapy and remains a major threat to patient survival. In this …
Bone marrow mesenchymal stem cells for improving hematopoietic function: an in vitro and in vivo model. Part 2: Effect on bone marrow microenvironment
S Carrancio, B Blanco, C Romo, S Muntion… - PloS one, 2011 - journals.plos.org
The aim of the present study was to determine how mesenchymal stem cells (MSC) could
improve bone marrow (BM) stroma function after damage, both in vitro and in vivo. Human …
improve bone marrow (BM) stroma function after damage, both in vitro and in vivo. Human …
Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's …
M Steinberg, M Silva - Clinical therapeutics, 2010 - Elsevier
Background: Autologous hematopoietic stem cell (HSC) transplantation is used to facilitate
hematopoietic recovery after administration of high-dose chemotherapy in patients with …
hematopoietic recovery after administration of high-dose chemotherapy in patients with …